European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis

Research output: Contribution to journalLetter

Abstract

Atopic dermatitis (AD) is a complex disease with elevated risk of respiratory comorbidities.1,2 Severely affected patients are often treated with immune-modulating systemic drugs.3,4 On March 11th 2020, the World Health Organization declared the 2019 novel coronavirus severe acute respiratory syndrome (SARS-Cov-2) epidemic to be a pandemic. The number of cases worldwide is increasing exponentially and poses a major health threat, especially for those who are elderly, immuno-compromised, or have comorbidities. This also applies to AD patients on systemic immune-modulating treatment. In these days of uncertainty, reallocation of medical resources, curfew, hoarding, and shutdown of normal social life, patients, caregivers and doctors ask questions regarding the continuation of systemic immune-modulating treatment of AD patients. The ETFAD decided to address some of these questions here.

Details

Authors
  • Andreas Wollenberg
  • Carsten Flohr
  • Dagmar Simon
  • Michael J. Cork
  • Jacob P. Thyssen
  • Thomas Bieber
  • Marjolein S. de Bruin-Weller
  • Stephan Weidinger
  • Mette Deleuran
  • Alain Taieb
  • Carle Paul
  • Magdalena Trzeciak
  • Thomas Werfel
  • Julien Seneschal
  • Sebastien Barbarot
  • Ulf Darsow
  • Antonio Torrelo
  • Jean Francois Stalder
  • Dirkjan Hijnen
  • Carlo Gelmetti
  • Zsuzsanna Szalai
  • Uwe Gieler
  • Linda De Raeve
  • Barbara Kunz
  • Phyllis Spuls
  • Regina Fölster-Holst
  • Pavel V. Chernyshov
  • Stéphanie Cristen-Zaech
  • Annice Heratizadeh
  • Johannes Ring
  • Christian Vestergaard
Organisations
External organisations
  • Guy's and St Thomas' NHS Foundation Trust
  • Bern University Hospital
  • University of Sheffield
  • Gentofte Hospital
  • University Hospital Bonn
  • University Medical Center Utrecht
  • University Medical Center Schleswig-Holstein Campus Kiel
  • Aarhus University Hospital
  • University of Bordeaux
  • University of Toulouse
  • Medical University of Gdansk
  • Hannover Medical School
  • Nantes University Hospital
  • Technical University of Munich
  • Hospital Infantil Universitario Niño Jesús
  • Skåne University Hospital
  • Erasmus University Medical Center
  • University of Milan
  • Heim Pal Children's Hospital
  • Justus Liebig University Giessen
  • Universitair Ziekenhuis Brussel
  • Academic Medical Center of University of Amsterdam (AMC)
  • National Medical University
  • Lausanne University Hospital
  • Christine Kühne Center for Allergy Research and Education (CK-CARE)
  • Ludwig-Maximilian University of Munich
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Dermatology and Venereal Diseases

Keywords

  • atopic dermatitis, COVID-19, immunosuppressant, SARS-CoV-2, systemic therapy
Original languageEnglish
JournalJournal of the European Academy of Dermatology and Venereology : JEADV
Publication statusAccepted/In press - 2020 Mar 29
Publication categoryResearch
Peer-reviewedYes